Project Scope This project team will create a White Paper with recommendations for Treatment Emergent Definitions, with a focus on Phase 2-4 clinical trials. This White Paper will build upon a White Paper that outlines results from a survey on current practices, indicating variation that can likely be reduced. Recommendations will be based on the desired end-in-mind, and may or may not be consistent with current practices. |
Project Leads | Emails |
---|---|
Mary Nilsson | |
William Palo | |
Wendy Dobson (PHUSE Project Manager) |
| ||||||
---|---|---|---|---|---|---|
The team are currently developing the scenarios for their survey and are working on an abstract for the EU Connect. |
Objectives & Deliverables | Timelines |
---|---|
White Paper with recommended definition(s) . | Q42021 |
Project Members | Organisation |
---|---|
Alan Shapiro | FDA |
Beilei Xu | Sanofi |
Carolyn Setze | AbbVie |
Cathy Bezek | Astellas |
Charles Beasley | MNS |
Elisa Young | Southern Star Research |
James Gaiser | Prometrika |
Joanne Zhou | GSK |
Jun Li | Sanofi |
Kim Musgrave | Amgen |
Project Members | Organisation |
Laura Goebel | Janssen Research & Development |
Melvin Munsaka | AbbVie |
Meredith Chuck | FDA |
Nancy Brucken | CSG |
Pranab Mitra | Industry |
Raj Phadtare | Corvus Pharma |
Ramaiah Muvvala | Inductive Quotient |
Russell Newhouse | Eli Lilly |
Simin K Baygani | Eli Lilly |
Tejas Patel | Booz Allen |